Nordson Reports Record Q2 Sales with Strong Growth and Revised Fiscal Year Guidance

Nordson Corporation (NDSN) reports a remarkable second quarter performance for fiscal 2026, emphasizing its growth trajectory and strategic initiatives. The company announces record sales of $741 million, reflecting an impressive 8% increase year-over-year, with 7% of that attributed to organic growth across all its segments. This success stems from a strengthened order entry momentum and a notable 18% increase in backlog when compared to the previous year. Nordson’s President and CEO, Sundaram Nagarajan, attributes this growth to heightened demand, particularly in the Medical and Fluid Solutions segments, which brings forth record sales figures amid expanding market opportunities and resilience in operational efficiency.

Strong Financial Performance

The financial results highlight an adjusted earnings per share (EPS) increase to $2.86, surpassing analyst expectations and demonstrating an 18% rise from the same period last year. Furthermore, the company's EBITDA reaches a staggering $235 million, comprising 32% of total sales. Free cash flow stands at $170 million, showcasing Nordson's capability to return value to shareholders while committing resources to future expansions. The solid performance across business segments, particularly in Industrial Precision Solutions and Medical, positions Nordson competitively within the industry while emphasizing the company's strategic focus on innovation to capture emerging market trends.

Future Growth Projections

Looking towards future growth, Nordson has revised its fiscal year 2026 guidance to reflect an anticipated revenue range of $2.93 billion to $3.01 billion, with an adjusted EPS forecast between $11.30 and $11.80. This upward adjustment underscores the company's robust backlog growth and sustained order momentum, suggesting that Nordson is not only thriving now but is also well-positioned for continued success. Importantly, Nordson maintains a pipeline for mergers and acquisitions, particularly in the medical and technology sectors, indicating a proactive approach to bolstering its capabilities and reach in a rapidly evolving market landscape.